Three Studies Support Medtronic’s Cryoablation Systems As ‘First Line’ AFib Treatment
Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.
You may also be interested in...
Two pivotal US trials of pulsed field ablation systems began in early March. Farapulse is sponsoring the ADVENT randomized trial of the Farapulse PFA system and Medtronic launched the international PULSED AF trial of its PulseSelect PFA system.
The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.
The series E financing will support the ongoing US trial of Adagio’s iCLAS cardiac cryoablation system and development of Adagio's pulsed field cryoablation technology while the company continues to commercialize iCLAS outside the US.